The TNXP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TNXP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TNXP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TNXP Detailed Price Forecast - CNN Money||View TNXP Detailed Summary - Google Finance|
|View TNXP Detailed Summary - Yahoo! Finance||View TNXP Stock Research & Analysis - Zacks.com|
|View TNXP Trends & Analysis - Trade-Ideas||View TNXP Major Holders - Barrons|
|View TNXP Call Transcripts - NASDAQ||View TNXP Breaking News & Analysis - Seeking Alpha|
|View TNXP Annual Report - CompanySpotlight.com||View TNXP OTC Short Report - OTCShortReport.com|
|View TNXP Fundamentals - TradeKing||View TNXP SEC Filings - Bar Chart|
|View Historical Prices for TNXP - The WSJ||View Performance/Total Return for TNXP - Morningstar|
|View the Analyst Estimates for TNXP - MarketWatch||View the Earnings History for TNXP - CNBC|
|View the TNXP Earnings - StockMarketWatch||View TNXP Buy or Sell Recommendations - MacroAxis|
|View the TNXP Bullish Patterns - American Bulls||View TNXP Short Pain Metrics - ShortPainBot.com|
|View TNXP Stock Mentions - StockTwits||View TNXP Stock Mentions - PennyStockTweets|
|View TNXP Stock Mentions - Twitter||View TNXP Investment Forum News - Investor Hub|
|View TNXP Stock Mentions - Yahoo! Message Board||View TNXP Stock Mentions - Seeking Alpha|
|View Insider Transactions for TNXP - SECform4.com||View Insider Transactions for TNXP - Insider Cow|
|View TNXP Major Holdings Summary - CNBC||View Insider Disclosure for TNXP - OTC Markets|
|View Insider Transactions for TNXP - Yahoo! Finance||View Institutional Holdings for TNXP - NASDAQ|
|View TNXP Stock Insight & Charts - FinViz.com||View TNXP Investment Charts - StockCharts.com|
|View TNXP Stock Overview & Charts - BarChart||View TNXP User Generated Charts - Trading View|
Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today
Posted on Friday December 07, 2018
Tonix Pharmaceuticals (NASDAQ:TNXP) says that it is holding a new public offering that has a total value of $15 billion. The company notes that it plans to use funds from this public offering to fuel a new Phase 3 study for TNX-102 SL, which is its lead product candidate. According to Tonix Pharmaceuticals, it will be selling Class A and Class B shares of its stock during the public offering.
Tonix Pharmaceuticals Prices $15,000,000 Public Offering
Posted on Friday December 07, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today the pricing of an underwritten public offering with expected total gross proceeds of $15,000,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to help fund a new Phase 3 study using a modified trial design for its lead product candidate, TNX-102 SL, and for working capital and other general corporate purposes. The securities offered by the Company consist of (i) Class A Units each consisting of one share of Common Stock and one Warrant to purchase one share of Common Stock at a price of $3.50 per Class A Unit, and (ii) Class B Units each consisting of one share of Series A Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into 286 shares of Common Stock per share of Series A Preferred Stock, and Warrants to purchase 286 shares of Common Stock, at a combined price of $1,000 per Class B Unit.
Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target
Posted on Monday December 03, 2018
NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Tonix Pharmaceuticals Holding Corp. (TNXP), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya, which has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD. New composition of matter patent was issued in November which expands the Company's intellectual property protection for Tonmya, or TNX-102 SL, in the U.S. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer's disease and fibromyalgia.
Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Posted on Thursday November 29, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), today announced that it has received the official minutes from the October 29th Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA). The minutes are consistent with the preliminary guidance the Company received at the meeting and confirm FDA’s acceptance of the new Phase 3 “RECOVERY” study design. As previously communicated, the Company plans to start the RECOVERY trial for the treatment of posttraumatic stress disorder (PTSD) in the first quarter of 2019.